Bavarian Nordic (private company)
See something wrong or missing? Let us know
Offices:Denmark, Germany, USA
Industry:
Biotech
Business model:
Bavarian Nordic is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases.
Developing cancer immunotherapies and vaccines for infectious diseases, Bavarian Nordic has a market cap of €1Bn (7.5Bn DKK) on the Nasdaq Copenhagen, and has over 400 employees worldwide.
Its PROSTVAC vaccine for cancer, based in a virus, has been under fire, but Bavarian Nordic’s pipeline in infectious disease seems solid, and includes a new programme for Ebola.
Investors:
we tracked 0 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Belgium
Netherlands
Austria
Germany
Switzerland
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
France
Ireland
Italy
Portugal
Spain
United Kingdom